Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of insulin degludec vs insulin glargine U100 using flash glucose monitoring in type 2 diabetes
2017-004047-20Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin degludec and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Percentage of time in glycaemic target range 70–180 mg/dL. Started Jun 2018; status: completed.
02
Drugs
insulin degludecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-004047-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004047-20.